GlassScriptPhysician profile
John R Vipperman
NPI 1992787980
$4,930.14
in general payments reported to CMS, 2019-2025
42 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.31 · 2023: $1,010 · 2024: $2,024 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,363 · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,362.86 |
| Education | $473.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.67 | 2023-2025 | Imfinzi, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $417.14 | 2023-2025 | Talvey, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $407.34 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $273.11 | 2023-2025 | |
| Tempus Ai, INC | $245.59 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $193.50 | 2024-2025 | Monjuvi, Pemazyre, Zynyz |
| Astellas Pharma US INC | $191.87 | 2023-2024 | Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $179.92 | 2023-2025 | Opdualag, Opdivo, Krazati |
| Gilead Sciences, INC. | $179.38 | 2024-2025 | Trodelvy |
| Abbvie INC. | $173.37 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $149.62 | 2023-2025 | Orgovyx |
| Pharmaessentia USA Corporation | $144.40 | 2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $143.19 | 2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $141.87 | 2024-2025 | Fruzaqla, Vonvendi |
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $122.95 | 2023-2025 | |
| Sobi, INC | $104.77 | 2023 | |
| Glaxosmithkline, LLC. | $95.34 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Novo Nordisk INC | $93.31 | 2021 | |
| Array Biopharma INC | $92.19 | 2025 | Mektovi, Braftovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $83.34 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $80.49 | 2024-2025 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $78.26 | 2023-2025 | |
| Seagen INC. | $74.99 | 2024 | |
| Genentech USA, INC. | $67.55 | 2023-2025 | Polivy, Lunsumio, Hemlibra |
| Exelixis INC. | $63.74 | 2024-2025 | Cabometyx |
| Stemline Therapeutics INC. | $56.89 | 2024-2025 | Orserdu |
| Genzyme Corporation | $56.44 | 2024-2025 | |
| Beigene USA, INC. | $56.20 | 2023-2025 | Brukinsa |
| Celgene Corporation | $54.39 | 2023-2024 | Reblozyl, Pomalyst |
| Beone Medicines USA, INC. | $54.19 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $40.39 | 2023-2024 | Fotivda |
| Daiichi Sankyo INC. | $24.87 | 2024 | Enhertu |
| Fennec Pharmaceuticals, INC. | $21.35 | 2023 | Pedmark |
| Puma Biotechnology, INC. | $21.04 | 2023 | Nerlynx |
| Novocure INC. | $19.32 | 2025 | Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $19.05 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $18.80 | 2024 | Krazati |
| Servier Pharmaceuticals LLC | $18.69 | 2025 | |
| Springworks Therapeutics, INC. | $14.66 | 2025 | Ogsiveo |
| Amgen INC. | $13.58 | 2023 | Nplate, Xgeva, Vectibix |
| Rigel Pharmaceuticals, INC. | $13.38 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vipperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.